The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OPRX | +162.9% | -31.66% | -7.33% | -94% |
| S&P | +13.96% | +91.24% | +13.85% | +459% |
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
OptimizeRx and Silvergate Capital are flying high this year. Here's why.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $26.07M | 22.3% |
| Gross Profit | $16.44M | 33.1% |
| Gross Margin | 63.05% | 5.1% |
| Market Cap | $380.58M | 169.1% |
| Market Cap / Employee | $2.95M | 0.0% |
| Employees | 129 | -5.1% |
| Net Income | $0.78M | 108.5% |
| EBITDA | $3.13M | 14127.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $19.52M | 21.0% |
| Accounts Receivable | $32.23M | 22.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $25.10M | -25.1% |
| Short Term Debt | $3.51M | 59.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.02% | 16.7% |
| Return On Invested Capital | -7.53% | -1.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.19M | 80.0% |
| Operating Free Cash Flow | $3.20M | 78.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.78 | 1.37 | 2.15 | 3.19 | 135.59% |
| Price to Sales | 0.97 | 1.70 | 2.45 | 3.64 | 127.09% |
| Price to Tangible Book Value | -30.90 | 260.69 | 278.94 | 77.27 | -243.78% |
| Price to Free Cash Flow TTM | 17.81 | 23.60 | 24.24 | 33.21 | - |
| Enterprise Value to EBITDA | 23.12 | -172.73 | 63.12 | 130.36 | -98.22% |
| Free Cash Flow Yield | 5.6% | 4.2% | 4.1% | 3.0% | - |
| Return on Equity | -16.5% | -12.9% | -8.2% | 0.0% | -100.14% |
| Total Debt | $33.19M | $32.80M | $28.98M | $28.61M | -19.90% |
No podcast episodes available.
OPRX earnings call for the period ending June 30, 2022.
OPRX earnings call for the period ending December 31, 2021.
OPRX earnings call for the period ending September 30, 2021.
OPRX earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
